<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690300</url>
  </required_header>
  <id_info>
    <org_study_id>I1-GOA-1</org_study_id>
    <secondary_id>EudraCT 2005-004236-40</secondary_id>
    <nct_id>NCT00690300</nct_id>
  </id_info>
  <brief_title>Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer</brief_title>
  <official_title>Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in
      patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of
      a palliative first line therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For years Fluorouracil was the established treatment for pancreatic cancer with median
      survival times up to 8 months. Since 1997 Gemcitabine is also a standard therapy with in
      comparison to Fluorouracil a significant better clinical benefit.

      But after progression of the disease under a palliative first-line therapy there is no
      established second line therapy for pancreatic cancer.

      So the purpose of this study is to test the combination of Oxaliplatin and Docetaxel in
      patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of
      a palliative first line therapy to get a reasonable second line concept.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor response</measure>
    <time_frame>12/2009 and end of the study 12/2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>12/2009 and end of study 12/2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>12/2009 and end of study 12/2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire for quality of life</measure>
    <time_frame>every three weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaire for clinical Benefit</measure>
    <time_frame>every week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity / safety</measure>
    <time_frame>every week</time_frame>
    <description>all adverse events will be documented every week with their correlation to Oxaliplatin and Docetaxel</description>
  </secondary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pancreas Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 IV on day 1 of each 22 day cycle</description>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>80 mg/m2 IV on day 2 of each 22 day cycle</description>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Dated and signed informed concent

          -  Histologically or cytologically proven metastatic or locally advanced adenocarcinoma
             of the exocrine pancreas (stadium UICC III/IV)

          -  Presence of at least one measurable (according to RECIST criteria) marker lesion
             (primary tumor or metastasis) outside of an area that was previously subjected to
             radiation therapy

          -  Failure of a palliative first line therapy of a metastatic or locally advanced
             adenocarcinoma of the exocrine pancreas due to: Progress within 3 months after a
             first-line therapy Discontinuation of a first-line therapy due to toxicity

          -  Age &gt;= 18 years

          -  Karnofsky index &gt; 60%

          -  Expected live span &gt; 12 weeks

          -  Sufficient bone marrow reserve: Granulocytes &gt;= 1.5 x 109/L and Platelets &gt;= 100 x
             109/L and Hemoglobin &gt;= 9 g/L

          -  Serum Bilirubin &lt; 2 x upper normal limit or 2.5 x upper normal limit in case of
             hepatic metastasis (biliary drainage allowed)

          -  AST/ALT &lt; 2.5 x upper normal limit

        Exclusion Criteria:

          -  Every other cancer or secondary cancer besides the basal cell carcinoma of the skin or
             the carcinoma in situ of the cervix uteri. Inclusion of patients with other types of
             cancer that were successfully treated and that did not relapse within the last 5 years
             is possible

          -  Pregnancy or lactation

          -  Patients able to reproduce that do not adhere to strict contraception

          -  Presence of brain metastasis

          -  Severe, uncontrolled infection

          -  Preexisting peripheral neuropathy &gt; grade I

          -  Preexisting severe illnesses such as unstable coronary artery disease or uncontrolled
             cardiac arrhythmia

          -  Justified disbelief in the compliance of the patient

          -  Parallel participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Seufferlein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Halle / Klinik für Innere Medizin I</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Seufferlein, Prof. Dr.</last_name>
    <phone>49-345-5572661</phone>
    <email>thomas.seufferlein@medizin.uni-halle.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Goetz von Wichert, PD Dr.</last_name>
    <phone>49-731-500-44748</phone>
    <email>goetz.wichert@uniklinik-ulm.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Städtische Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden Württemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Geissler, Prof. Dr.</last_name>
      <phone>49-711-3103-2451</phone>
      <email>m.geissler@kliniken-es.de</email>
    </contact>
    <investigator>
      <last_name>Michael Geissler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Hoerner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Klausner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Winkler, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hartmut Mahrhofer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <state>Baden Württemberg</state>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
      <email>holger.hebart@klinikum.sgd.de</email>
    </contact>
    <investigator>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Grimminger, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Klinik für Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <state>Baden Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Goetz von Wichert, PD Dr.</last_name>
      <phone>49-731-500-44748</phone>
      <email>goetz.wichert@uniklinik-ulm.de</email>
    </contact>
    <contact_backup>
      <last_name>Jochen Klaus, Dr.</last_name>
      <phone>49-731-500-44727</phone>
      <email>jochen.klaus@uniklinik-ulm.de</email>
    </contact_backup>
    <investigator>
      <last_name>Goetz von Wichert, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sven Walter, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Klaus, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine Schulte, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heiko Fensterer, Dr.</last_name>
      <phone>49-6421-286-6460</phone>
      <email>heiko.fensterer@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Heiko Fensterer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Michl, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Mueller, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Innere Medizin I / Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Seufferlein, Prof. Dr.</last_name>
      <phone>+ 49 345 557 2661</phone>
      <email>thomas.seufferlein@medizin.uni-halle.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Seufferlein, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petra Büchner-Steudel, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Porzner, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Thermann, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Zipprich, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <last_update_submitted>March 2, 2010</last_update_submitted>
  <last_update_submitted_qc>March 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Thomas Seufferlein</name_title>
    <organization>University Halle-Wittenberg</organization>
  </responsible_party>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>pancreas carcinoma</keyword>
  <keyword>advanced pancreatic cancer</keyword>
  <keyword>metastatic pancreatic cancer</keyword>
  <keyword>second line</keyword>
  <keyword>palliative</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Taxotere</keyword>
  <keyword>Eloxatin</keyword>
  <keyword>Cancer of pancreas</keyword>
  <keyword>Pancreas cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

